Dementia, Vascular
Recent clinical, regulatory, research and industry developments relating to this disease.
Epidemiology of Vascular Dementia.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q2 2028.
- Q2 2028A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
- Q4 2028AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
- Q2 2029A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
- Q2 2029A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
- Q3 2029An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
Clinical MilestonesView all 15Hide
- 2026-04-16Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's DiseaseResults posted
- 2026-02-24A Randomised Double-blind Placebo-controlled Clinical Study Investigating the Effects of Semaglutide s.c. Once-weekly Versus Placebo on Central and Peripheral Inflammation in Participants With Alzheimer's DiseaseResults posted
- 2026-07-27A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's DiseaseResults expected Q2 2028
- 2026-07-07An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACMResults expected Q3 2029
- 2026-06-04AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)Results expected Q4 2028
- 2026-04-07A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's DiseaseResults expected Q2 2029
- 2026-03-05The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's DiseaseResults expected Q2 2030
- 2026-05-12Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's DiseaseCompleted
- 2026-01-30A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)Completed
- 2026-01-30A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)Completed
- 2025-09-23Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early DementiaCompleted
- 2026-04-01Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's DiseaseWithdrawn
- 2026-03-11Long-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 GenotypeTerminated
- 2026-01-06A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin GeneTerminated
- 2026-07-27ClinicalA Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's DiseaseResults expected Q2 2028
- 2026-07-07ClinicalAn Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACMResults expected Q3 2029
- 2026-06-04ClinicalAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)Results expected Q4 2028
- 2026-05-12ClinicalAssessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's DiseaseCompleted
- 2026-04-16ClinicalBiomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's DiseaseResults posted
- 2026-04-07ClinicalA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's DiseaseResults expected Q2 2029
- 2026-04-01ClinicalHistidine Oral Supplementation as a Therapeutic Modality for Alzheimer's DiseaseWithdrawn
- 2026-03-11ClinicalLong-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 GenotypeTerminated
- 2026-03-05ClinicalThe Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's DiseaseResults expected Q2 2030
- 2026-02-24ClinicalA Randomised Double-blind Placebo-controlled Clinical Study Investigating the Effects of Semaglutide s.c. Once-weekly Versus Placebo on Central and Peripheral Inflammation in Participants With Alzheimer's DiseaseResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Dementia, Vascular2
- Neuronal Plasticity2
- Alzheimer Disease1
- Extracellular Vesicles1
- Fluorodeoxyglucose F181
- Hippocampus1
- Memory Disorders1
- Mental Disorders1
Leading journals6
- Acta neuropathologica communications1
- Arteriosclerosis, thrombosis, and vascular biology1
- BMJ (Clinical research ed.)1
- Brain and behavior1
- Stroke1
- The Lancet. Neurology1
Leading researchers8
- Agosta F1
- Arbizu J1
- Arnett DK1
- Barkhof F1
- Barthel H1
- Bennett DA1
- Black SE1
- Brooks DJ1
Affiliations (unnormalised)6
- Alzheimer Center1
- Amsterdam University Medical Center1
- Beijing Key Laboratory of Sports Function Assessment and Technical Analysis1
- Center for Alzheimer Research1
- Center for Lifespan Changes in Brain and Cognition1
- Centre des Maladies Cognitives et Comportementales1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Vascular dementia is an imprecise term for dementia associated with cerebrovascular disorders, including single or multiple cerebral infarctions and conditions linked to chronic brain ischemia. Described subtypes include diffuse, cortical, and subcortical forms. It is part of the broader spectrum of vascular contributions to cognitive impairment and dementia.
It is associated with cerebrovascular disorders, especially cerebral infarction and chronic brain ischemia. The literature also describes vascular components such as atherosclerosis, arterio(l)o sclerosis, microinfarcts, and amyloid angiopathy as contributors to cognitive decline in later life. Cerebrovascular disease is often present alongside other causes of dementia rather than acting as the sole cause.
The disease reflects cognitive impairment arising from vascular injury to the brain, including infarction and chronic ischemic damage. White matter hyperintensities are studied as imaging markers associated with stroke, cognitive decline, and dementia, consistent with underlying small-vessel and ischemic brain injury. The literature also highlights neuropathology, basic science, and pathophysiological aspects of vascular contributions to dementia, including neuronal plasticity as a co-studied mechanism.
A history of stroke increases later dementia risk, and the prevention of recurrent stroke is emphasized as a key preventive strategy. More broadly, vascular risk is linked to cerebrovascular disease and white matter hyperintensities, which are associated with cognitive decline and dementia. The literature also notes vascular and other associated risk factors in vascular cognitive impairment and dementia.
Management is described at the level of prevention and treatment of vascular contributions to cognitive impairment and dementia, with emphasis on preventing and treating cerebrovascular disease. The reviewed literature highlights stroke prevention, including prevention of recurrent stroke, as a cornerstone. Diagnostic and management discussions also include neuroimaging and biomarker-based evaluation, but no specific drug class is established in the supplied grounding.
AI-generated summary grounded in MeSH and 4 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.